Vagus Nerve Stimulation as a Treatment for POTS and Dysautonomia

Vagus nerve stimulation (VNS) has been used in medicine for decades — primarily for epilepsy and treatment-resistant depression. But over the past several years, a growing body of research has begun to examine its potential for a very different set of conditions: POTS, dysautonomia, and related autonomic disorders. The results are promising, and for many patients who have exhausted conventional options, VNS represents a genuinely new direction.

The Rationale: Why Stimulate the Vagus Nerve?

The core problem in most forms of dysautonomia is an imbalance between the sympathetic ("fight or flight") and parasympathetic ("rest and digest") branches of the autonomic nervous system. The vagus nerve is the primary conduit of the parasympathetic system. In POTS and related conditions, vagal tone is typically reduced — the nerve is underactive, allowing the sympathetic system to dominate.

Vagus nerve stimulation works by directly activating vagal fibers, effectively boosting parasympathetic tone. This can slow the heart rate, improve baroreflex sensitivity, reduce sympathetic outflow, modulate the immune system, and improve gut motility — all of which are relevant to dysautonomia symptoms.

Types of Vagus Nerve Stimulation

Invasive VNS (iVNS)

The original form of VNS involves surgically implanting a small pulse generator (similar to a pacemaker) under the skin of the chest. A lead wire is wrapped around the left vagus nerve in the neck. The device delivers regular electrical pulses to the nerve, typically for 30 seconds every 5 minutes.

Invasive VNS is FDA-approved for epilepsy and treatment-resistant depression. Its use in dysautonomia is off-label and uncommon due to the surgical risks involved. However, case reports and small studies have documented improvements in autonomic function in patients who received iVNS for other indications and also had dysautonomia.

Non-Invasive VNS (nVNS)

Non-invasive approaches have transformed the accessibility of VNS research. There are two main forms:

Transcutaneous Cervical VNS (tcVNS / gammaCore): A handheld device placed against the neck that delivers electrical pulses through the skin to the vagus nerve. The gammaCore device (electroCore) is FDA-cleared for cluster headache and migraine. Research in POTS is ongoing.

Transcutaneous Auricular VNS (taVNS / tVNS): The ear contains the auricular branch of the vagus nerve (also called the Arnold's nerve), which can be stimulated non-invasively using small electrodes placed on the outer ear — specifically the cymba conchae or tragus. This approach is the most widely studied in dysautonomia research.

Clinical Evidence in POTS

The evidence base for VNS in POTS has grown substantially since 2020:

A landmark randomized controlled trial published in the Journal of the American College of Cardiology: Electrophysiology in 2024 found that non-invasive VNS significantly reduced orthostatic tachycardia compared to sham stimulation in POTS patients. This was the first rigorous RCT to demonstrate efficacy specifically in POTS, and it has accelerated interest in this approach.

A 2026 study in Shiffer et al. specifically examined Hyper-POTS patients over 14 days of transcutaneous VNS and found improvements in cardiovagal modulation, reduced sympathetic activity, and measurable improvement in orthostatic symptoms — a particularly encouraging result given that Hyper-POTS is one of the more treatment-resistant subtypes.

How VNS Helps: Proposed Mechanisms

Researchers have proposed several mechanisms by which VNS improves dysautonomia symptoms:

Baroreflex restoration: The baroreflex is the body's rapid blood pressure regulation system. VNS appears to improve baroreflex sensitivity, helping the body respond more effectively to positional changes.

Sympathetic suppression: By activating the nucleus tractus solitarius (NTS) in the brainstem — the primary relay for vagal signals — VNS can reduce sympathetic outflow, lowering resting heart rate and blunting the tachycardic response to standing.

Anti-inflammatory effects: The vagus nerve carries the cholinergic anti-inflammatory pathway. VNS activates this pathway, reducing circulating inflammatory cytokines. This is particularly relevant for autoimmune POTS and MCAS, where inflammation plays a central role.

HRV improvement: Multiple studies have shown that tVNS increases HRV, a direct marker of improved vagal tone and autonomic flexibility.

Non-Device Approaches to Vagal Stimulation

For patients who cannot access VNS devices, several evidence-informed lifestyle approaches can modestly improve vagal tone:

Slow, diaphragmatic breathing: Breathing at approximately 6 breaths per minute (5 seconds in, 5 seconds out) activates the baroreflex and increases HRV. This is the basis of HRV biofeedback therapy, which has demonstrated benefits in several autonomic conditions.

Cold water immersion of the face: The diving reflex — triggered by cold water on the face — powerfully activates the vagus nerve, slowing the heart rate. Even splashing cold water on the face can produce a measurable vagal response.

Humming, singing, and gargling: The vagus nerve innervates the muscles of the larynx and pharynx. Vibration from humming or gargling activates vagal afferents in the throat.

Exercise (recumbent and aquatic): Aerobic exercise, particularly in recumbent or supine positions (to minimize orthostatic stress), has been shown to improve vagal tone over time. The CHOP protocol and similar structured exercise programs for POTS are partly effective through this mechanism.

Meditation and slow yoga: Practices that emphasize slow breathing and parasympathetic activation can improve HRV over weeks to months of consistent practice.

Current Limitations and Future Directions

The evidence for VNS in dysautonomia is promising but still emerging. Key limitations include:

• Most studies are small (fewer than 50 participants)
• Stimulation parameters (frequency, intensity, duration, timing) vary widely between studies, making comparisons difficult
• Long-term effects beyond 2–4 weeks are not well characterized
• Non-invasive devices are not yet FDA-approved specifically for POTS or dysautonomia
• Access and cost remain barriers; consumer-grade tVNS devices are available but not covered by most insurance for these indications

Several larger trials are currently underway, including a NIH-funded multicenter study examining taVNS in POTS. The field is moving quickly, and it is likely that non-invasive VNS will become a recognized treatment option within the next several years.

Practical Considerations

If you are interested in exploring VNS:

• Discuss with your autonomic specialist or cardiologist — they can advise on whether you are an appropriate candidate and monitor your response.
• Consumer-grade tVNS devices (such as the Nurosym or Parasym) are available for purchase and have been used in several research studies. They are not FDA-approved for dysautonomia but are generally considered low-risk.
• HRV biofeedback apps (such as Elite HRV or Visible) can help you practice slow breathing techniques and track your vagal tone over time.
• Start with non-device approaches (slow breathing, cold water, exercise) before investing in a device.

VNS is not a cure for dysautonomia, but for many patients it represents a meaningful addition to a comprehensive treatment plan — one that addresses the underlying autonomic imbalance rather than just managing individual symptoms.

---

This article is for educational purposes only and does not constitute medical advice. Always consult a qualified healthcare provider before starting any new treatment.